The Relative Strength (RS) Rating for Avidity Biosciences jumped into a new percentile Friday, with an increase from 70 to 81.
Looking For The Best Stocks To Buy And Watch? Start Here
This proprietary rating identifies market leadership by using a 1 (worst) to 99 (best) score that shows how a stock's price action over the trailing 52 weeks matches up against other publicly traded companies.
History reveals that the top-performing stocks often have an RS Rating north of 80 in the early stages of their moves.
While now is not an ideal time to buy shares, see if the stock manages to form a chart pattern and break out.
The company reported 0% EPS growth in its most recent report. Sales increased -56%.
The company holds the No. 266 rank among its peers in the Medical-Biomed/Biotech industry group. Exelixis, Catalyst Pharmaceuticals and ADMA Biologics are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Which Stocks Are Showing Rising Relative Strength?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
